Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease

Jia Song, Yan Kang, LiNa Wang, YuQing Guo, XinJu Jia, ShanShan Dong, YiMeng Li, Dan Wang, JingMin Gao and AiGe Yang

PLOS ONE, 2025, vol. 20, issue 8, 1-14

Abstract: Aims: This study aimed to investigate the efficacy and safety of finerenone in the treatment of diabetic kidney disease (DKD) in the real-world medical setting and explore the underlying mechanism of its kidney-protecting effects from the perspective of the inflammatory response. Materials and Methods: Forty-eight DKD patients were selected and completed a 6-month finerenone treatment. Renal parameters, inflammatory cytokines, other related indicators and adverse effects were collected at every visit. Additionally, subgroup analysis was conducted on the microalbuminuria group (baseline urinary albumin/creatinine ratio (UACR) 30 –

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0329965 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 29965&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0329965

DOI: 10.1371/journal.pone.0329965

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().